Irbesartan

From Wikipedia, the free encyclopedia

Irbesartan
Systematic (IUPAC) name
2-butyl-
3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-
1,3-diazaspiro[4.4]non-1-en-4-one
Identifiers
CAS number 138402-11-6
ATC code C09CA04
PubChem 3749
DrugBank APRD00413
Chemical data
Formula C25H28N6O 
Mol. mass 428.53
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability 60–80%
Metabolism Hepatic (CYP2C9)
Half life 11–15 hours
Excretion Renal 20%, faecal 65%
Therapeutic considerations
Licence data

EU, US
Pregnancy cat.

D (Au)
Legal status

S4 (Au), POM (UK), ℞-only (U.S.)
Routes Oral

Irbesartan (INN) (pronounced /ɜrbəˈsɑrtən/) is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. Irbesartan was developed by Sanofi Research (now part of sanofi-aventis). It is jointly marketed by sanofi-aventis and Bristol-Myers Squibb under the trade names Aprovel, Karvea, and Avapro.

Contents

[edit] Clinical use

Main article: Angiotensin II receptor antagonist

[edit] Indications

As with all angiotensin II receptor antagonists, irbesartan is indicated for the treatment of hypertension. Irbesartan may also delay progression of diabetic nephropathy and is also indicated for the reduction of renal disease progression in patients with type 2 diabetes,[1] hypertension and microalbuminuria (>30 mg/24 hours) or proteinuria (>900 mg/24 hours).[2]

[edit] Combination with diuretic

Irbesartan is also available in a combination formulation with a low dose thiazide diuretic, invariably hydrochlorothiazide, to achieve an additive antihypertensive effect. Irbesartan/hydrochlorothiazide combination preparations are marketed under similar trade names to irbesartan preparations, including CoAprovel, Karvezide, Avalide and Avapro HCT.

[edit] References

  1. ^ Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. (2001). "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.". N Engl J Med 345 (12): 851-60. doi:10.1056/NEJMoa011303. PMID 11565517. 
  2. ^ Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3

[edit] See also

v • d • e
Agents acting on the renin-angiotensin system (C09)
ACE inhibitors
Angiotensin II receptor antagonists (AIIRA)
Azilsartan • Candesartan • Eprosartan • Irbesartan • Losartan • Olmesartan • Tasosartan • Telmisartan • Valsartan
Renin inhibitors